Current board positions:Vital Trace : Vitaltrace.com.auRH Capital Board: RHCAPITAL.vc Ross University Board of Trustees: Adtalem.com (parent company)Intellihealth Inc. Advisory Board: Intellihealth.com

- Managing ~80 employees, strategically guided $750 million in annual investments in new technologies and service delivery models in low and middle-income countries.- Oversaw annual investment budget increase from $170 million to $750 million during tenure.- Built a commercialization strategy for innovation introduction to address dual markets (private/public sectors; middle-income/low-income countries). - Created first strategic collaborative structure between upstream R&D and the Maternal, Newborn and Child Health/Family Planning/Nutrition teams. - Hired new director-level leaders, providing year-long executive coaching to facilitate onboarding and ensure strategic alignment. - Led negotiations with big pharma to secure market supply of a novel contraceptive technology.- Led collaborative work initiatives with Global Finance Facility, World Bank, USAID, and WHO using data-based evidence to influence global investment, policy, and practice.

- Led strategy and investiment portfolio for the Maternal Newborn Child Health program strategy team in the Global Development Division. Strategic focus geographies in Africa and South Asia. - Built strong collaboration between upstream R&D aligning pre-market trial endpoints with downstream postmarket implementaion reseach to inform scaling of disruptive technologies and new service delivery models. - External collaborators included multilaterals, bilaterals, and governments. - Focus populations include public sector and women and infants in underserved areas where maternal and infant mortality and morbidity is highest globally.

Established Corporate Safety Office, setting central corporate policy and strategy of Medical Safety across Medtronic’s ($30 billion) 4 major global business groups. Managed a core team of 25 and decentralized matrix team of 65. - Directly managed escalation and resolution of device related global safety events.Integrated and standardized a new model of medical safety operations for clinical and post market surveillance tested for success. VP, Chief Medical Officer, Early Technologies Business (2014 – 2017)VP, Chief Safety Officer, Minimally Invasive Technology Group (legacy Covidien) (2014 – 2017)- Led Medical Affairs operations and strategy for the Global Early Technology Business: innovative and - disruptive diagnostic and therapeutic interventions (pulmonary and GI Pillcam Endoscopy), product development, clinical development pathway pre-and post-market, business development (focus on due diligence), market introduction (professional societies and training). Provided representation to FDA, EMEA, TGA, PMD.- Built the first Covidien safety office to provide centrally managed clinical trial, post market safety oversight, and case resolution. Trained and managed a core team of 25 to provide Medical Safety oversight for Covidien ($13 billion business) and expanded this model at Medtronic post-acquisition.

Covidien acquired by Medtronic in 2014Vice President Global Medical Affairs, Surgical Solutions Business Group for Developed and Emerging Markets, (2014 – 2015)- Led operations and strategy leadership of Global Surgical Business medical affairs.Vice President Global Medical Affairs; CMO, Surgical Solutions Business Group | Developed and Emerging Markets (2012 – 2014)- Oversaw Medical Affairs for all combined businesses in Japan, Australia, and China.Vice President, Global Medical Affairs, STI/EMID/Energy (2011 -2012)- Oversaw all Medical Affairs across 3 business groups (140 employees) for US, Japan, Australia, New Zealand, and Canada.Global Medical Director, Soft Tissue Implants, Lyon, France (2010- 2011) - As a surgeon, provided clinical and strategic inputs to the pre-clinical and clinical development pathway (clinical research, product development, post-market vigilance, healthcare economics, regulatory, and multinational medical education) for a synthetic and biologic mesh product innovation for hernia. - Led the corporate response to FDA ban of transvaginal pelvic mesh use.

Commons Capital LP (venture capital impact fund with a double bottom line) 2008 - 2010Consultant, Subject Matter Expert, Clinical AdvisorParticipated in model development; seed fund raising;due diligence.

Rockefeller Foundation, Population Council, Wellcome Trust, Packard Foundation

Late-stage medical device company/ female urology Board Member, Consultant, Subject Matter Expert Regulatory, reimbursement, and payer meeting company representative.Led medical device training.

Hologic Corp. / Cytec Corp. / Adiana Inc., Redwood City, CA Adiana was acquired by Cytec in 2007; Cytec was subsequently acquired by Hologic.Medical Consultant, Hologic (2008-2009) - Built team of experts needed for PMA submission and stayed through PMA approval and design work for FDA required post-market studies.- Medical Consultant, Cytec (2007 – 2008)Retained post acquisition to complete regulatory planning and conclude pivotal trial Chief Medical Officer, Adiana Inc. (2006 – 2007)- Led final stages of pivotal clinical trial, negotiations with the FDA, outcome analytics. Partnered with the CEO through the company’s acquisition.

International health care organization | 400 employees | 30 countriesChief Executive Officer (1996 – 2006)- Managed a non-profit budget ($40 million) for growth.- Served an international Board of Directors- Led international women’s health policy/regulatory initiatives for HPV vaccine, obstetric fistula, and emerging markettechnologies.- As technical expert, negotiated with and served US government, multilaterals (FDA, UN, WHO, Global Fund), and countrygovernments (Africa, Asia, Latin America) on emerging market technologies.  • Increased budget by 40% while reducing governmental funding dependence from 95% to 45%.• Received UNFPA Population Award.Chief Medical Officer (1991 – 1996)- Rebuilt medical staff for expansion, operating on three continents.- Led clinical trials for regulated products in Africa, Asia, and Latin America.